California 2021-2022 Regular Session

California Senate Bill SB306

Introduced
2/4/21  
Refer
2/17/21  
Refer
2/17/21  
Refer
3/9/21  
Refer
3/9/21  
Refer
3/24/21  
Report Pass
4/8/21  
Report Pass
4/8/21  
Refer
4/8/21  
Refer
4/8/21  
Report Pass
4/19/21  
Report Pass
4/19/21  
Refer
4/19/21  
Report Pass
5/24/21  
Engrossed
6/2/21  
Refer
6/10/21  
Report Pass
6/23/21  
Refer
6/23/21  
Refer
6/23/21  
Report Pass
7/6/21  
Refer
7/6/21  
Report Pass
8/26/21  
Enrolled
9/10/21  
Chaptered
10/4/21  
Chaptered
10/4/21  

Caption

Sexually transmitted disease: testing.

Impact

The implications of SB 306 extend to improving access to healthcare by mandating insurance coverage for home test kits for STDs, along with associated laboratory costs, provided these services are deemed medically necessary. This is particularly significant for Medi-Cal and the Family PACT Program beneficiaries, as it encompasses low-income individuals who may otherwise face barriers accessing timely testing and treatment. Furthermore, the legislation aims to empower HIV counselors to conduct STD testing, thereby expanding the qualified workforce capable of addressing STDs within communities, especially among youth and marginalized populations.

Summary

Senate Bill No. 306, approved by the Governor on October 4, 2021, seeks to address the growing concerns surrounding sexually transmitted diseases (STDs) in California. The bill amends several sections of the Business and Professions Code, Health and Safety Code, Insurance Code, and Welfare and Institutions Code to streamline testing and treatment protocols for STDs. It introduces the concept of 'expedited partner therapy' (EPT), allowing healthcare providers to prescribe antibiotics to the sexual partners of individuals diagnosed with STDs without a direct examination of those partners. This aspect aims to improve treatment outreach and decrease transmission rates of STDs.

Sentiment

General sentiment surrounding the bill has been largely supportive among public health advocates who recognize the critical need for comprehensive STD testing and treatment in light of rising infection rates exacerbated by the COVID-19 pandemic. However, there are concerns regarding the implications of liability protections for healthcare providers and pharmacists involved in expedited partner therapy. Critics argue that while the bill attempts to facilitate care, it may overshadow the need for more robust preventive measures and education about STDs, particularly in vulnerable communities significantly affected by health disparities.

Contention

Notable points of contention include the balance between increasing accessibility to treatment and ensuring thorough medical oversight for patients. Proponents view the liability protections as essential to encourage healthcare providers and pharmacists to engage in the expedited partner therapy program without fear of legal repercussions, provided they adhere to legal standards. Opponents, however, voice concerns that such measures could dilute the quality of care individuals receive, potentially leading to oversights in comprehensive public health strategies that prioritize prevention and education alongside treatment.

Companion Bills

No companion bills found.

Similar Bills

CA SB1191

Medi-Cal: pharmacogenomic testing.

CA AB425

Medi-Cal: pharmacogenomic testing.

CA SB885

Sexually transmitted diseases.

CA SB524

Pharmacists: furnishing prescription medications.

CA SB159

HIV: preexposure and postexposure prophylaxis.

CA AB1929

Medi-Cal benefits: violence prevention services.

CA SB1234

Family Planning, Access, Care, and Treatment Program.

CA SB541

Sexual health: contraceptives.